{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=vismodegib+%28GDC-0449%29&page=3", "query": { "intervention": "vismodegib (GDC-0449)", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 52, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=vismodegib+%28GDC-0449%29&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=vismodegib+%28GDC-0449%29&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T13:09:10.985Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00887159", "title": "A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extensive Stage Small Cell Lung Carcinoma", "Recurrent Small Cell Lung Carcinoma" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cixutumumab", "type": "BIOLOGICAL" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Vismodegib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 168, "start_date": "2009-07-16", "completion_date": "2016-11-15", "has_results": true, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-10-08T13:09:10.985Z", "location_count": 301, "location_summary": "Scottsdale, Arizona • Palo Alto, California • Aurora, Colorado + 205 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00887159" }, { "nct_id": "NCT01878617", "title": "A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Medulloblastoma" ], "interventions": [ { "name": "Craniospinal Irradiation with boost to the primary tumor site", "type": "RADIATION" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Vismodegib", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Aerobic Training", "type": "OTHER" }, { "name": "Neurocognitive Remediation", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "DRUG", "OTHER" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "3 Years to 39 Years" }, "enrollment_count": 660, "start_date": "2013-06-23", "completion_date": "2031-10-13", "has_results": false, "last_update_posted_date": "2025-11-13", "last_synced_at": "2026-10-08T13:09:10.985Z", "location_count": 14, "location_summary": "Palo Alto, California • San Diego, California • New Haven, Connecticut + 11 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01878617" }, { "nct_id": "NCT00957229", "title": "To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Basal Cell Nevus Syndrome", "Gorlin Syndrome" ], "interventions": [ { "name": "GDC-0449", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCSF Benioff Children's Hospital Oakland", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "35 Years to 75 Years" }, "enrollment_count": 41, "start_date": "2009-08", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2021-01-11", "last_synced_at": "2026-10-08T13:09:10.985Z", "location_count": 2, "location_summary": "Oakland, California • New York, New York", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00957229" }, { "nct_id": "NCT01898598", "title": "A Study of Vismodegib With Surgery in Participants With Previously Untreated Basal Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Basal Cell Carcinoma" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Vismodegib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2014-01-23", "completion_date": "2016-01-26", "has_results": true, "last_update_posted_date": "2017-05-08", "last_synced_at": "2026-10-08T13:09:10.985Z", "location_count": 21, "location_summary": "Scottsdale, Arizona • Beverly Hills, California • La Jolla, California + 17 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01898598" }, { "nct_id": "NCT00939484", "title": "Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Medulloblastoma" ], "interventions": [ { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Vismodegib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 31, "start_date": "2009-06", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2016-02-25", "last_synced_at": "2026-10-08T13:09:10.985Z", "location_count": 13, "location_summary": "Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00939484" }, { "nct_id": "NCT02067104", "title": "Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Basal Cell Carcinomas" ], "interventions": [ { "name": "Vismodegib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2014-02-17", "completion_date": "2016-12-31", "has_results": true, "last_update_posted_date": "2019-08-14", "last_synced_at": "2026-10-08T13:09:10.985Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02067104" }, { "nct_id": "NCT02639117", "title": "Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Basal Cell Carcinoma" ], "interventions": [ { "name": "Vismodegib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2015-11-30", "completion_date": "2017-11-18", "has_results": false, "last_update_posted_date": "2018-07-18", "last_synced_at": "2026-10-08T13:09:10.985Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02639117" }, { "nct_id": "NCT01195415", "title": "Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Pancreatic Carcinoma", "Stage IV Pancreatic Cancer" ], "interventions": [ { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Vismodegib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2010-06", "completion_date": "2014-10-10", "has_results": true, "last_update_posted_date": "2017-08-07", "last_synced_at": "2026-10-08T13:09:10.985Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01195415" }, { "nct_id": "NCT01330173", "title": "Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "DS Stage I Plasma Cell Myeloma", "DS Stage II Plasma Cell Myeloma", "DS Stage III Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Vismodegib", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2010-12", "completion_date": "2014-11", "has_results": false, "last_update_posted_date": "2014-12-23", "last_synced_at": "2026-10-08T13:09:10.985Z", "location_count": 2, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01330173" }, { "nct_id": "NCT01154452", "title": "Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Alveolar Soft Part Sarcoma", "Adult Angiosarcoma", "Adult Desmoplastic Small Round Cell Tumor", "Adult Epithelioid Hemangioendothelioma", "Adult Epithelioid Sarcoma", "Adult Extraskeletal Myxoid Chondrosarcoma", "Adult Extraskeletal Osteosarcoma", "Adult Fibrosarcoma", "Adult Leiomyosarcoma", "Adult Liposarcoma", "Adult Malignant Mesenchymoma", "Adult Malignant Peripheral Nerve Sheath Tumor", "Adult Rhabdomyosarcoma", "Adult Synovial Sarcoma", "Adult Unclassified Pleomorphic Sarcoma", "Chondrosarcoma", "Clear Cell Sarcoma of the Kidney", "Conjunctival Kaposi Sarcoma", "Dermatofibrosarcoma Protuberans", "Gastrointestinal Stromal Tumor", "Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Metastatic Osteosarcoma", "Ovarian Sarcoma", "Recurrent Adult Soft Tissue Sarcoma", "Recurrent Adult Unclassified Pleomorphic Sarcoma of Bone", "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Recurrent Kaposi Sarcoma", "Recurrent Osteosarcoma", "Recurrent Uterine Corpus Sarcoma", "Small Intestine Leiomyosarcoma", "Stage III Adult Soft Tissue Sarcoma", "Stage III Uterine Sarcoma", "Stage IV Adult Soft Tissue Sarcoma", "Stage IV Uterine Sarcoma", "Unclassified Pleomorphic Sarcoma of Bone" ], "interventions": [ { "name": "Gamma-Secretase Inhibitor RO4929097", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Vismodegib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2010-06", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2018-08-15", "last_synced_at": "2026-10-08T13:09:10.985Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01154452" } ] }